{"organizations": [], "uuid": "9bfa76de8e021112b1de96bc156deaa9ea22d64f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-redhill-biopharma-announces-two-or/brief-redhill-biopharma-announces-two-oral-presentations-on-bekinda-24-mg-for-acute-gastroenteritis-idUSFWN1R90JI", "country": "US", "domain_rank": 408, "title": "BRIEF-Redhill Biopharma Announces Two Oral Presentations On Bekinda速 24 Mg For Acute Gastroenteritis", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-27T15:09:00.000+03:00", "replies_count": 0, "uuid": "9bfa76de8e021112b1de96bc156deaa9ea22d64f"}, "author": "", "url": "https://www.reuters.com/article/brief-redhill-biopharma-announces-two-or/brief-redhill-biopharma-announces-two-oral-presentations-on-bekinda-24-mg-for-acute-gastroenteritis-idUSFWN1R90JI", "ord_in_thread": 0, "title": "BRIEF-Redhill Biopharma Announces Two Oral Presentations On Bekinda速 24 Mg For Acute Gastroenteritis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-redhill biopharma", "sentiment": "negative"}, {"name": "redhill biopharma ltd", "sentiment": "none"}, {"name": "bekinda", "sentiment": "none"}, {"name": "mg for acute gastroenteritis reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 13 PM / Updated 18 minutes ago BRIEF-Redhill Biopharma Announces Two Oral Presentations On Bekinda速 24 Mg For Acute Gastroenteritis Reuters Staff 1 Min Read March 27 (Reuters) - Redhill Biopharma Ltd: * REDHILL BIOPHARMA ANNOUNCES TWO ORAL PRESENTATIONS ON BEKINDA速 24 MG FOR ACUTE GASTROENTERITIS AT THE SAEM 2018 ANNUAL MEETING * REDHILL BIOPHARMA -RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III GUARD STUDY WITH BEKINDA 24 MG SUCCESSFULLY MET ITS PRIMARY ENDPOINT * BEKINDA 24 MG WAS ALSO FOUND TO BE SAFE AND WELL TOLERATED IN TREATMENT OF ACUTE GASTROENTERITIS AND GASTRITIS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)", "external_links": [], "published": "2018-03-27T15:09:00.000+03:00", "crawled": "2018-03-27T15:35:48.000+03:00", "highlightTitle": ""}